Co-Diagnostics, Inc. (CODX) is a molecular diagnostics company that designs, produces, and globally markets specialized reagents. These components are integral to diagnostic tests that identify and analyze nucleic acid molecules. The company's product portfolio features the Co-Dx PCR platform, enabling Polymerase Chain Reaction (PCR) testing for patients in both clinical (point-of-care) and home settings. They offer an extensive range of PCR diagnostic tests for numerous conditions, including COVID-19, influenza, tuberculosis, hepatitis B and C, human papillomavirus, malaria, chikungunya, dengue, and the zika virus. Beyond human health, Co-Diagnostics develops three distinct multiplexed tests for screening mosquitos to detect disease-carrying pathogens. Their advanced molecular tools also serve broader applications, encompassing infectious disease detection, liquid biopsy for cancer screening, and agricultural uses such as identifying genetic traits in plant and animal genomes. Complementing these offerings is a portable diagnostic device, specifically engineered to make PCR testing accessible directly to patients in various settings. The company was founded in 2013 and is based in Salt Lake City, Utah.

Employees - 132, CEO - Dwight H. Egan, Sector - Healthcare, Country - US, Market Cap -

Altman ZScore(max is 10): -12.72, Piotroski Score(max is 10): 1, Working Capital: $5497651, Total Assets: $21499726, Retained Earnings: $-89513577, EBIT: -50130165, Total Liabilities: $5457316, Revenue: $718166

AryaFin Target Price - $7.85 - Current Price $ - Analyst Target Price $